DNA Methylation of RUNX3 in Papillary Thyroid Cancer.
10.3904/kjim.2012.27.4.407
- Author:
Hee Ja KO
1
;
Bo Yeon KIM
;
Chan Hee JUNG
;
Sung Wan CHUN
;
Ji Oh MOK
;
Yeo Joo KIM
;
Hyeong Kyu PARK
;
Chul Hee KIM
;
Sang Jin KIM
;
Dong Won BYUN
;
Kyo Il SUH
;
Myung Hi YOO
;
Sung Gu KANG
Author Information
1. Department of Internal Medicine, Soonchunhyang University College of Medicine, Cheonan, Korea. ksj1113@schmc.ac.kr
- Publication Type:Original Article
- Keywords:
Methylation;
Thyroid neoplasms;
RUNX3
- MeSH:
Azacitidine/analogs & derivatives/pharmacology;
Carcinoma/*genetics;
Cell Line, Tumor;
Core Binding Factor Alpha 3 Subunit/*genetics;
DNA Methylation/drug effects;
Gene Expression/drug effects;
Humans;
Thyroid Neoplasms/*genetics;
Tumor Markers, Biological/genetics
- From:The Korean Journal of Internal Medicine
2012;27(4):407-410
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND/AIMS: The relationship between Runt-related transcription factor 3 (RUNX3) gene inactivation and various solid tumors has been reported; however, little information is available about RUNX3 in thyroid cancers. METHODS: We evaluated the DNA methylation of RUNX3 in 13 papillary thyroid cancer tissues and four thyroid cancer cell lines. Additionally, using reverse transcriptase-polymerase chain reaction, we analyzed RUNX3 gene expression in several thyroid cancer cell lines after treating with the demethylating agent 5-aza-2'-deoxycytidine (DAC). RESULTS: RUNX3 was hypermethylated in many thyroid cancer cell lines and in 10 of the 12 papillary thyroid cancer tissues. Treatment with DAC increased the expression of RUNX3 in some thyroid cancer cell lines. CONCLUSIONS: We suggest that RUNX3 is associated with thyroid carcinogenesis, and RUNX3 methylation is a potentially useful diagnostic marker for papillary thyroid cancer.
